| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
IQVIA Holdings, Inc.$233.36
-1.66 (-0.71%)
B 70Pipeline Score Tools & Services · Commercial
Market Cap
28.02 B
EPS
8.14
P/E Ratio
20.81 $
Value Trade
279.98 M
SEC Financials
Q1 2026Dilution Risk
Revenue
4.15 B
Operating CF
618.00 M
Total Assets
29.68 B
Total Liabilities
23.33 B
Equity
6.22 B
-1.28 %
Week
-5.85 %
1 Month
-0.24 %
3 Month
-22.77 %
6 Month
-29.26 %
5 Year
283.68 %
All Time
Cash Data
Cash Position
2.10 B
Monthly Burn
-
Runway
-
Burn Trend
StableSEC Filing
May 5, 2026
Overview
Volume
1.64 M
52 Week Range
136.41 - 247.05
% held by Insiders
0.98 %
% held by Institutions
100.96 %
Enterprise Value
42.11 B
Total Shares
166.90 M
Short %
3.23 %
Float Shares
157.89 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for IQVIA Holdings, Inc.
104Total events
1Upcoming
9Tier-1 (high impact)
2013 – 2026Coverage
Upcoming catalysts 1
TBD
T2Timing Guidance
Subscribe to view catalyst details
Event history 2
TBD
●Quarterly UpdateCorporate
Subscribe to view catalyst details
TBD
▼Equity OfferingCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
B70
Pipeline Score $20.2B
Pipeline ValueValuation Signal
22
Drugs Scored2.4x
rNPV / MCap Top 95%
Mid Cap (rank 47 of 923)
Percentile RankIQVIA Holdings, Inc. holds a solid B-grade pipeline (70/100), with $23.7B risk-adjusted pipeline value, led by Atezolizumab in Advanced Solid Tumor (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Atezolizumab Small molecule | Non-Small Cell Lung Cancer | Phase 2 | NCT03976518 | 19% | $8.7B | COMPLETED | 43 | - | - | Feb 12, 2024 | - | Mar 1, 2024 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in IQV
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
IQV Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
IQV▲ +13.9%on this news
IQVIA Reports Second-Quarter 2026 Results
IQVIA Holdings Inc. has announced its financial results for the second quarter of 2026, showcasing a positive performance compared to the previous year. The company has also implemented a new organizational model aimed at improving collaboration and efficiency. This strategic move is expected to further strengthen its position in the clinical research and healthcare intelligence sectors.
Read more →IQVIQVIA's Dr. Cynthia Verst Testifies Before Congressional Subcommittee on More Efficient Path to Early Clinical Development in the United States
Dr. Cynthia Verst from IQVIA testified before the U.S. House Committee on Energy and Commerce, emphasizing the need for reforms to enhance early clinical development in the United States. Her recommendations aim to position the U.S. as a leader in biomedical innovation. The hearing focused on the FDA's role in advancing these initiatives.
Read more →IQVIQVIA to Announce Second-Quarter 2026 Results on July 28, 2026
IQVIA Holdings Inc. will announce its second-quarter 2026 financial results on July 28, 2026, before market opening. The management team will conduct a conference call and webcast at 9:00 a.m. Eastern Time on the same day, providing insights into the company's performance.
Read more →IQVStackAdapt Teams Up with IQVIA Digital’s MediaOS to Power Healthcare Advertising
StackAdapt has partnered with IQVIA Digital's MediaOS to enhance healthcare advertising efforts. This collaboration emphasizes the importance of privacy in advertising, aiming to provide more effective solutions for healthcare marketers. The integration of these technologies is expected to drive innovation in the sector.
Read more →IQVWiley and IQVIA Release Cross-Sector Report on AI’s Promise and Pressure Points Across Healthcare Value Chain
Wiley and IQVIA have collaborated to release a report focusing on the implications of artificial intelligence across the healthcare value chain. The report highlights both the potential benefits and challenges associated with AI integration in healthcare. Further details about the findings and recommendations are expected to be elaborated upon in subsequent communications.
Read more →IQVIQVIA Announces Pricing of Senior Notes
IQVIA Holdings Inc. has announced the pricing of an offering of $950 million in senior notes due 2033. The proceeds from this offering will be utilized to refinance existing indebtedness and cover the related fees and expenses. These notes will accrue interest at a rate of 4.625% annually, with the initial interest payment beginning on December 15, 2026. The issuance is expected to finalize around June 11, 2026, subject to typical closing conditions.
Read more →IQVIQVIA Announces Offering of Senior Notes - June 3, 2026
IQVIA Holdings Inc. announced its intention to raise €950 million through a senior notes offering due in 2033. The proceeds will be utilized to refinance existing debt and cover related fees. The offering is contingent upon market conditions and other customary factors, highlighting potential risks involved.
Read more →IQVIQVIA Announces Offering of Senior Notes
IQVIA has announced an offering of senior notes, although specific details regarding the amount or purpose of the offering are not provided in the article. The announcement is part of the company's ongoing financial strategies. Further information may be released in subsequent communications.
Read more →IQVIQVIA CEO to Speak at Jefferies Global Healthcare Conference
IQVIA's CEO is scheduled to speak at the Jefferies Global Healthcare Conference. The event is expected to provide insights into the company's strategies and future directions. However, specific details about the topics to be discussed have not been disclosed.
Read more →IQVIQVIA and Kexing Biopharm Expand Strategic Collaboration to Accelerate Global Biosimilar Development using AI-Enabled Capabilities
IQVIA and Kexing Biopharm have announced an expansion of their strategic collaboration. The partnership aims to enhance global biosimilar development by leveraging AI-enabled capabilities. This initiative is expected to streamline processes and improve efficiency in the biopharmaceutical sector.
Read more →IQVKerri Joseph, IQVIA Investor Relations (kerri.joseph@iqvia.com) +1.973.541.3558 Alissa Maupin, IQVIA Media Relations (alissa.maupin1@iqvia.com) +1.919.923.6785 IQVIA Board of Directors Approves $2
IQVIA Holdings Inc. has announced that its Board of Directors has authorized a $2 billion increase in its share repurchase program, raising the total remaining authorization to $3.2 billion. This decision reflects the company's robust financial position and willingness to invest in its own shares. The repurchase program offers flexibility for management to respond to market conditions. IQVIA continues its focus on delivering high-quality healthcare insights and solutions powered by AI and advanced analytics.
Read more →IQVIQVIA Board of Directors Approves $2 Billion Increase in Share Repurchase Authorization
IQVIA's Board of Directors has approved a significant increase in its share repurchase authorization by $2 billion. This decision reflects the company's commitment to enhancing shareholder value. However, the article lacks detailed information on the implications or context surrounding this decision.
Read more →IQVIQVIA CFO to Speak at Bank of America Health Care Conference 2026
IQVIA's CFO is scheduled to speak at the upcoming Bank of America Health Care Conference in 2026. This event is anticipated to provide insights into the company's strategies and outlook. Further details about the conference agenda and topics of discussion have not been disclosed.
Read more →IQV▲ +9.6%on this newsshared move
IQVIA Reports First-Quarter 2026 Results
IQVIA has released its financial results for the first quarter of 2026. The report highlights the company's performance metrics and financial health. However, specific details regarding revenue, profit, or other financial indicators were not disclosed in the article.
Read more →IQVIQVIA to Announce First-Quarter 2026 Results on May 5, 2026
IQVIA Holdings Inc. will announce its first-quarter 2026 financial results on May 5, 2026, before the market opens. The management team will host a conference call and webcast at 9:00 a.m. Eastern Time on the same day. Interested parties must register in advance to participate in the call.
Read more →IQVIQVIA Unveils IQVIA.ai, a Unified Agentic AI Platform Powered by NVIDIA to Improve Efficiency and Decision Making Across Life Sciences
IQVIA has launched IQVIA.ai, a new AI platform designed to enhance decision-making and efficiency in life sciences. This platform integrates advanced analytics and automation, allowing organizations to streamline operations and improve research capabilities. The collaboration with NVIDIA has resulted in over 100 AI-related patents, showcasing IQVIA's commitment to innovation in healthcare. The initial release will target high-value use cases across various domains.
Read more →IQVIQVIA CEO to Speak at Leerink Partners 2026 Global Healthcare Conference
IQVIA Holdings Inc. announced that CEO Ari Bousbib will speak at the Leerink Partners 2026 Global Healthcare Conference on March 9, 2026. The presentation will be available via a live audio webcast on the IQVIA Investor Relations website. This event underscores IQVIA's role as a leader in clinical research and healthcare intelligence.
Read more →IQVIQVIA CFO to Speak at Barclays 28th Annual Global Healthcare Conference
IQVIA Holdings Inc. announced that its CFO, Mike Fedock, will speak at the Barclays 28th Annual Global Healthcare Conference on March 12, 2026. The event will include a live audio webcast available on the company's Investor Relations website. IQVIA is known for its commitment to healthcare intelligence and clinical research services.
Read more →IQVIQVIA Signs Agreement to Acquire Drug Discovery Assets from Charles River Laboratories, Expanding End-to-End Drug Discovery Capabilities
IQVIA has announced an agreement to acquire drug discovery assets from Charles River Laboratories, which includes five specialized sites for in vitro drug discovery. This acquisition aims to enhance IQVIA's end-to-end drug discovery capabilities, integrating advanced methodologies and AI platforms. The transaction is expected to close in the second quarter, expanding IQVIA's service offerings in various therapeutic areas.
Read more →IQV▼ -5.3%on this news
IQVIA and Duke Clinical Research Institute Announce Strategic Collaboration to Advance Clinical Research in Obesity and Related Conditions
IQVIA and the Duke Clinical Research Institute have announced a strategic collaboration aimed at advancing clinical research in obesity and related conditions. This partnership combines IQVIA's operational capabilities with DCRI's academic expertise to enhance trial efficiency and accelerate the delivery of therapies. With extensive experience in obesity trials, the collaboration is expected to improve patient care and set new benchmarks in clinical research.
Read more →IQV▼ -10.7%on this newsshared move
IQVIA Reports Fourth-Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance
IQVIA Holdings Inc. reported strong financial results for Q4 and full-year 2025, with revenue growth across all segments. The company achieved near double-digit growth in revenue and earnings per share, and its R&DS contracted backlog grew significantly. For 2026, IQVIA expects continued growth in revenue and adjusted EBITDA, despite anticipated increases in interest expenses.
Read more →IQVIQVIA and Boehringer Ingelheim announce strategic long-term global commercial data foundation transformation collaboration
IQVIA has announced a long-term collaboration with Boehringer Ingelheim to enhance its global commercial data capabilities. Utilizing IQVIA’s Data-as-a-Service (DaaS+) platform, Boehringer aims to harmonize its data across various therapeutic areas and regions. This partnership is expected to drive efficiencies in data operations and support upcoming product launches.
Read more →IQVIQVIA to Announce Fourth-Quarter and Full-Year 2025 Results on February 5, 2026
IQVIA Holdings Inc. will announce its fourth-quarter and full-year 2025 financial results on February 5, 2026. The announcement will be made before market opening, followed by a conference call and webcast at 9:00 a.m. ET. Interested parties must register in advance to participate in the call.
Read more →IQVIQVIA Announces Strategic Collaboration with AWS, Naming AWS as Preferred Agentic Cloud Provider to Power Next-Generation AI Platform
IQVIA has announced a strategic collaboration with Amazon Web Services (AWS), designating AWS as its Preferred Agentic Cloud Provider. This partnership aims to enhance clinical trial automation and healthcare analytics through an innovative AI platform. The collaboration seeks to democratize AI in life sciences, improving drug innovation and patient outcomes globally.
Read more →IQVKerri Joseph, IQVIA Investor Relations (kerri.joseph@iqvia.com) +1.973.541.3558 Alissa Maupin, IQVIA Media Relations (alissa.maupin1@iqvia.com) +1.919.923.6785 Dr. William G. Kaelin Jr. joins IQVIA Board of Dire
IQVIA announced the appointment of Dr. William G. Kaelin Jr. to its board of directors. Dr. Kaelin, a Nobel Prize winner, is a prominent physician-scientist known for his work in oncology and hypoxia signaling. He joins the board amidst IQVIA's commitment to advancing biomedical innovation and improving patient outcomes worldwide. His extensive background and achievements are expected to add valuable insights to the company's strategic direction.
Read more →IQVKerri Joseph, IQVIA Investor Relations (kerri.joseph@iqvia.com) +1.973.541.3558 Alissa Maupin, IQVIA Media Relations (alissa.maupin1@iqvia.com) +1.919.923.6785 IQVIA Announces CFO Transition in Earl
IQVIA Holdings Inc. has announced a planned CFO transition set for February 28, 2026, with Michael Fedock taking over from the retiring Ron Bruehlman. Fedock, currently serving as Senior VP of Financial Planning & Analysis, brings extensive experience and a strong relationship with CEO Ari Bousbib. Bruehlman will remain with the company as a Senior Advisor, ensuring continuity during this change. This transition is a strategic move aimed at maintaining IQVIA's growth trajectory in the life sciences industry.
Read more →IQVIQVIA Reports First-Quarter 2024 Results Revenue of $3,737 million GAAP Net Income of $288 million, Adjusted EBITDA of $862 million GAAP Diluted Earnings per Share of $1.56, Adjusted Diluted Earnings per Share of $2.54 R
IQVIA Holdings Inc. reported its financial results for the first quarter of 2024, highlighting a revenue of $3,737 million, a 2.3% increase year-over-year. The company’s R&D Solutions segment showed significant growth with a backlog of $30.1 billion. For the full year, IQVIA reaffirmed its revenue guidance, despite anticipating foreign exchange challenges. The company reported strong adjusted earnings per share and cash flow generation during the quarter.
Read more →IQV▲ +13.1%on this news
IQVIA Reports Fourth-Quarter and Full-Year 2023 Results; Issues Full-Year 2024 Guidance Revenue of $3,868 million for the fourth quarter, $14,984 million for the full year GAAP Net Income of $469 million for the fourth q
IQVIA reported strong financial results for the fourth quarter and full year of 2023, with a notable increase in revenue and net income. The company achieved fourth-quarter revenue of $3,868 million and a GAAP net income of $469 million, representing significant year-over-year growth. For 2024, IQVIA issued guidance projecting revenue between $15,400 million to $15,650 million, despite anticipating a reduction in COVID-related revenue. Additionally, the contracted backlog for R&D Solutions continued to grow, indicating solid demand in its services.
Read more →IQVIQVIA Announces Offering of Senior Secured Notes
IQVIA Holdings Inc. has announced plans to offer $500 million in senior secured notes due in 2029. The funds collected from this offering, along with an expected amendment to its senior secured credit facilities, will be allocated to repay certain outstanding loans and cover associated fees. However, the success of this financial strategy hinges on several market conditions and is not assured, as the amendments and new loans are not contingent upon the completion of the notes offering. This move aims to enhance IQVIA's financial stability in serving the life sciences sector.
Read more →IQVIQVIA Reports Third-Quarter 2023 Results Revenue of $3,736 million grew 4.9 percent year-over-year GAAP Net Income of $303 million grew 7.1 percent year-over-year Adjusted EBITDA of $888 million grew 9.1 percent year-ove
IQVIA reported its third-quarter results for 2023, revealing a revenue increase of 4.9% year-over-year, reaching $3,736 million. The company also reported a GAAP net income growth of 7.1% and a notable rise in its research and development backlog. However, adjusted diluted earnings per share showed only modest growth at 0.4%. Looking forward, IQVIA updated its revenue guidance, reflecting potential challenges in the Technology & Analytics Solutions segment amid a strengthening U.S. dollar.
Read more →IQVNEWS Contact: Nick Childs, IQVIA Investor Relations (nick.childs@iqvia.com) +1.973.316.3828 Trent Brown, IQVIA Media Relations (trent.brown@iqvia.com) +1.919.780.3221 IQVIA Appoints Richard Staub III President of Researc
IQVIA has appointed Richard Staub III as the new president of its Research & Development Solutions business unit. Staub, who previously served in this role from 2016 to 2022, has been a senior advisor to the Chairman and CEO and is recognized for his leadership during the expansion of IQVIA's clinical research capabilities. He replaces Costa Panagos, who will retire after a 24-year career at the company. IQVIA continues to emphasize its commitment to advanced analytics and technology solutions in life sciences.
Read more →IQVIQVIA Reports Second-Quarter 2023 Results Revenue of $3,728 million grew 5.3 percent year-over-year on a reported basis and 5.5 percent at constant currency GAAP Net Income of $297 million grew 16.0 percent year-over-yea
IQVIA reported its second-quarter 2023 financial results, showing a revenue increase of 5.3% year-over-year to $3,728 million and a GAAP Net Income growth of 16.0% to $297 million. The company achieved an Adjusted EBITDA of $864 million, up by 8.0%, while maintaining a strong contracting backlog of $28.4 billion, which is expected to convert into revenue over the next twelve months. Despite some challenges in revenue from Contract Sales & Medical Solutions, overall performance showcases resilience in a challenging market.
Read more →IQVIQVIA Announces Offering of Senior Secured Notes and Senior Notes
IQVIA Holdings Inc. announced a plan to raise $1 billion through an offering of senior secured notes due 2028 and senior notes due 2030. The funds will be used primarily to repay outstanding borrowings and cover associated fees and expenses. However, the successful completion of this offering is contingent on market conditions and other factors that present potential risks, including the possibility of failure to complete the offering.
Read more →IQVIQVIA Reports First-Quarter 2023 Results; Reaffirms Full-Year 2023 Guidance Revenue of $3,652 million GAAP Net Income of $289 million, Adjusted EBITDA of $851 million GAAP Diluted Earnings per Share of $1.53, Adjusted Di
IQVIA Holdings Inc. reported first-quarter 2023 results, announcing a revenue of $3,652 million, an increase from the prior year. The company reaffirmed its full-year guidance, expecting revenues between $15,150 million and $15,400 million, reflecting healthy underlying growth despite some challenges in discretionary spending. A notable increase in R&D Solutions backlog signifies strong demand, though the Contract Sales & Medical Solutions sector saw a decline in revenue. Overall, IQVIA maintains a positive outlook with a strong operational performance.
Read more →IQVIQVIA Reports Fourth-Quarter and Full-Year 2022 Results; Issues Full-Year 2023 Guidance Revenue of $3,739 million for the fourth quarter, $14,410 million for the full year GAAP Net Income of $227 million for the fourth q
IQVIA reported its financial results for Q4 and full-year 2022, showing a revenue of $3,739 million for Q4 and $14,410 million for the full year. Despite a decrease in GAAP Net Income and Diluted EPS, the company experienced growth in R&D Solutions and significant backlog figures. For 2023, IQVIA expects revenue growth between 5.1% and 6.9%, while also projecting increased earnings and EBITDA. The outlook remains largely optimistic, driven by continued demand in their market segments.
Read more →IQVIQVIA Reports Third-Quarter 2022 Results Revenue of $3,562 million grew 5.0 percent year-over-year on a reported basis and 10.5 percent at constant currency GAAP Net Income of $283 million grew 8.4 percent year-over-year
IQVIA Reports Third-Quarter 2022 Results Revenue of $3,562 million grew 5.0 percent year-over-year on a reported basis and 10.5 percent at constant currency GAAP Net Income of $283 million grew 8.4 percent year-over-year Adjusted EBITDA of $814 million increased 11.8 percent y
Read more →IQVIQVIA Reports Second-Quarter 2022 Results Revenue of $3,541 million grew 3.0 percent year-over-year on a reported basis and 7.1 percent at constant currency GAAP Net Income of $256 million grew 46.3 percent year-over-yea
IQVIA Reports Second-Quarter 2022 Results Revenue of $3,541 million grew 3.0 percent year-over-year on a reported basis and 7.1 percent at constant currency GAAP Net Income of $256 million grew 46.3 percent year-over-year Adjusted EBITDA of $800 million grew 10.8 percent year-
Read more →IQVIQVIA Reports First-Quarter 2022 Results Revenue of $3,568 million increased 4.7 percent year-over-year on a reported basis and 6.8 percent at constant currency GAAP Net Income of $325 million grew 53.3 percent year-over
IQVIA Reports First-Quarter 2022 Results Revenue of $3,568 million increased 4.7 percent year-over-year on a reported basis and 6.8 percent at constant currency GAAP Net Income of $325 million grew 53.3 percent year-over-year Adjusted EBITDA of $812 million grew 9.1 percent ye
Read more →IQVNEWS Contact Nick Childs, IQVIA Investor Relations (nick.childs iqvia.com) +1.973.316.3828 Tor Constantino, IQVIA Media Relations (tor.constantino iqvia.com) +1.484.567.6732 IQVIA Appoints Costa Panagos President of Rese
Contact Nick Childs, IQVIA Investor Relations (nick.childs iqvia.com) Tor Constantino, IQVIA Media Relations (tor.constantino iqvia.com) IQVIA Appoints Costa Panagos President of Research Development Solutions (R DS) RESEARCH TRIANGLE PARK, N.C. - March 14, 2022 - IQVIA Holdin
Read more →IQVIQVIA Reports Fourth-Quarter and Full-Year 2021 Results; Raises Full-Year 2022 Profit Guidance Revenue of $3,636 million for the fourth quarter grew 10.2 percent year-over-year on a reported basis and 11.6 percent at con
IQVIA Reports Fourth-Quarter and Full-Year 2021 Results; Raises Full-Year 2022 Profit Guidance Revenue of $3,636 million for the fourth quarter grew 10.2 percent year-over-year on a reported basis and 11.6 percent at constant currency GAAP Net Income of $318 million for the fou
Read more →IQVNick Childs, IQVIA Investor Relations (nick.childs@iqvia.com) +1.973.316.3828 Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com) +1.484.567.6732 Leslie Wims Morris Joins IQVIA Board
Contacts: Nick Childs, IQVIA Investor Relations (nick.childs@iqvia.com) +1.973.316.3828 Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com) +1.484.567.6732 Leslie Wims Morris Joins IQVIA Board of Directors RESEARCH TRIANGLE PARK, N.C. January 24, 2022 IQVI
Read more →IQVIQVIA Reports Third-Quarter 2021 Results and Raises Full-Year 2021 Guidance Revenue of $3,391 million for the third quarter grew 21.7 percent year-over-year GAAP Net Income of $261 million for the third quarter grew 158.
IQVIA Reports Third-Quarter 2021 Results and Raises Full-Year 2021 Guidance Revenue of $3,391 million for the third quarter grew 21.7 percent year-over-year GAAP Net Income of $261 million for the third quarter grew 158.4 percent year-over-year Adjusted EBITDA of $728 million
Read more →IQVIQVIA Reports Second-Quarter 2021 Results and Raises Full-Year 2021 Guidance Revenue of $3,438 million for the second quarter grew 36.4 percent year-over-year GAAP Net Income of $175 million for the second quarter increa
IQVIA Reports Second-Quarter 2021 Results and Raises Full-Year 2021 Guidance Revenue of $3,438 million for the second quarter grew 36.4 percent year-over-year GAAP Net Income of $175 million for the second quarter increased from $(23) million in 2020 Adjusted EBITDA of $722 mi
Read more →IQVIQVIA Reports First-Quarter Results; Raises Full-Year 2021 Guidance Revenue of $3,409 million for the first quarter grew 23.8 percent year-over-year Adjusted EBITDA of $744 million for the first quarter increased 32.4 pe
IQVIA Reports First-Quarter Results; Raises Full-Year 2021 Guidance Revenue of $3,409 million for the first quarter grew 23.8 percent year-over-year Adjusted EBITDA of $744 million for the first quarter increased 32.4 percent year-over-year GAAP Diluted Earnings per Share of $
Read more →IQVAndrew Markwick, IQVIA Investor Relations (andrew.markwick@iqvia.com) +1.973.257.7144 Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com) +1.484.567.6732 IQVIA Acquires Remaining Interest in Q 2
Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com) IQVIA Acquires Remaining Interest in Q2 Solutions from Quest Year 2021 Adjusted Diluted EPS Guidance DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C. April 1, 2021 IQVIA Holdings Inc. ( IQVIA ) (NYSE:IQV), a lead
Read more →IQVIQVIA Announces Pricing of Offering of Senior Notes
Announces Pricing of Offering of Senior Notes DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C. IQVIA Holdings Inc. ( IQVIA ) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the Issuer ), priced an offering of 1,450,000,000 in aggregate principal amount of
Read more →IQVIQVIA Reports Fourth-Quarter and Full-Year 2020 Results Raises Full-Year 2021 Guidance Revenue of $3,298 million for the fourth quarter grew 13.9 percent year-over-year Adjusted EBITDA of $735 million for the fourth quar
IQVIA Reports Fourth-Quarter and Full-Year 2020 Results Raises Full-Year 2021 Guidance Revenue of $3,298 million for the fourth quarter grew 13.9 percent year-over-year Adjusted EBITDA of $735 million for the fourth quarter increased 14.5 percent year-over-year GAAP Diluted E
Read more →IQVIQVIA Reports Third-Quarter 2020 Results, Raises Full-Year 2020 Guidance and Provides 2021 Outlook Third quarter revenue of $2,786 million and Adjusted EBITDA of $604 million GAAP Diluted Earnings per Share of $0.52 and
IQVIA Reports Third-Quarter 2020 Results, Raises Full-Year 2020 Guidance and Provides 2021 Outlook Third quarter revenue of $2,786 million and Adjusted EBITDA of $604 million GAAP Diluted Earnings per Share of $0.52 and Adjusted Diluted Earnings per Share of $1.63 Technology &
Read more →IQVIQVIA Reports Second-Quarter 2020 Results and Raises Full-Year 2020 Guidance Second quarter revenue $2,521 million and Adjusted EBITDA $483 million GAAP Diluted Earnings per Share $(0.12); Adjusted Diluted Earnings per S
IQVIA Reports Second-Quarter 2020 Results and Raises Full-Year 2020 Guidance Second quarter revenue $2,521 million and Adjusted EBITDA $483 million GAAP Diluted Earnings per Share $(0.12); Adjusted Diluted Earnings per Share $1.18 R&D Solutions quarterly net book-to-bill ratio
Read more →IQVTor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com) +1.484.567.6732 Andrew Markwick, IQVIA Investor Relations (andrew.markwick@iqvia.com) +1.973.257.7144 IQVIA Appoints Ron Bruehlman Executive Vic
Contact: Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com) +1.484.567.6732 Andrew Markwick, IQVIA Investor Relations (andrew.markwick@iqvia.com) +1.973.257.7144 IQVIA Appoints Ron Bruehlman Executive Vice President and interim Chief Financial Officer & RE
Read more →IQVIQVIA Reports First-Quarter 2020 Results; Issues Second-Quarter 2020 Guidance and Updates Full-Year 2020 Guidance First quarter revenue $2,754 million and Adjusted EBITDA $562 million GAAP Diluted Earnings per Share $0.4
IQVIA Reports First-Quarter 2020 Results; Issues Second-Quarter 2020 Guidance and Updates Full-Year 2020 Guidance First quarter revenue $2,754 million and Adjusted EBITDA $562 million GAAP Diluted Earnings per Share $0.42; Adjusted Diluted Earnings per Share $1.50 R&D Solution
Read more →IQVAndrew Markwick, IQVIA Investor Relations (andrew.markwick@iqvia.com) +1.973.257.7144 Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com) +1.484.567.6732 IQVIA provides update on business conditi
Contacts: Andrew Markwick, IQVIA Investor Relations (andrew.markwick@iqvia.com) +1.973.257.7144 Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com) +1.484.567.6732 IQVIA provides update on business conditions in light of COVID-19 and provides revised first
Read more →IQVIQVIA Reports Fourth-Quarter and Full-Year 2019 Results Issues First-Quarter and Full-Year 2020 Guidance Revenue of $2,895 million for the fourth quarter and $11,088 million for the full year Adjusted EBITDA of $642 mill
IQVIA Reports Fourth-Quarter and Full-Year 2019 Results Issues First-Quarter and Full-Year 2020 Guidance Revenue of $2,895 million for the fourth quarter and $11,088 million for the full year Adjusted EBITDA of $642 million for the fourth quarter and $2,400 million for the ful
Read more →IQVIQVIA Reports Third-Quarter 2019 Results Third-quarter revenue $2,769 million Adjusted EBITDA $593 million GAAP Diluted Earnings per Share $0.29; Adjusted Diluted Earnings per Share $1.60 Technology and Analytics Solutio
IQVIA Reports Third-Quarter 2019 Results Third-quarter revenue $2,769 million Adjusted EBITDA $593 million GAAP Diluted Earnings per Share $0.29; Adjusted Diluted Earnings per Share $1.60 Technology and Analytics Solutions adds 20 new Orchestrated Customer Engagement (OCE) wi
Read more →IQVIQVIA Announces Pricing of Offering of Senior Notes DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)
IQVIA Announces Pricing of Offering of Senior Notes DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--July 30, 2019--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the "Issuer"), priced an offering of 720,000,
Read more →IQVIQVIA Announces Offering of Senior Notes DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)
IQVIA Announces Offering of Senior Notes DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--July 29, 2019--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the "Issuer"), intends to raise $800,000,000 equivalent
Read more →IQVIQVIA Reports Second-Quarter 2019 Results, Raises Full-Year Revenue and Adjusted Diluted EPS Guidance Second-quarter revenue $2,740 million Adjusted EBITDA $578 million GAAP Diluted Earnings per Share $0.30; Adjusted Dil
IQVIA Reports Second-Quarter 2019 Results, Raises Full-Year Revenue and Adjusted Diluted EPS Guidance Second-quarter revenue $2,740 million Adjusted EBITDA $578 million GAAP Diluted Earnings per Share $0.30; Adjusted Diluted Earnings per Share $1.53 $236 million of share repu
Read more →IQVIQVIA Reports First-Quarter 2019 Results, Reaffirms Full-Year Guidance First-quarter revenue $2,684 million and Adjusted EBITDA $587 million GAAP Diluted Earnings per Share $0.29; Adjusted Diluted Earnings per Share $1.5
Reports First-Quarter 2019 Results, Reaffirms Full-Year Guidance revenue $2,684 million and Adjusted EBITDA $587 million Diluted Earnings per Share $0.29; Adjusted Diluted Earnings per Share constant currency organic revenue growth of 7.0 percent in Technology & Analytics Sol
Read more →IQVTor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com) +1.484.567.6732 Andrew Markwick, IQVIA Investor Relations (andrew.markwick@iqvia.com) +1.973.257.7144 Carol J. Burt Joins IQVIA Board of Directo
Contact: Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com) +1.484.567.6732 Andrew Markwick, IQVIA Investor Relations (andrew.markwick@iqvia.com) +1.973.257.7144 Carol J. Burt Joins IQVIA Board of Directors DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C. Fe
Read more →IQVIQVIA Reports Fourth-Quarter and Full-Year 2018 Results, Issues First-Quarter and Full-Year 2019 Guidance Revenue of $2,688 million for the fourth quarter and $10,412 million for the full year Adjusted EBITDA of $583 mil
Reports Fourth-Quarter and Full-Year 2018 Results, Issues First-Quarter and Full-Year 2019 Guidance of $2,688 million for the fourth quarter and $10,412 million for the EBITDA of $583 million for the fourth quarter and $2,224 million for Diluted Earnings per Share of $0.34 fo
Read more →IQVIQVIA Reports Third-Quarter 2018 Results and Updates Full-Year 2018 Guidance Revenue $2,594 million, up 6.3 percent at constant currency and 5.2 percent reported Adjusted EBITDA $561 million, up 8.4 percent at constant c
Reports Third-Quarter 2018 Results and Updates Full-Year 2018 Guidance $2,594 million, up 6.3 percent at constant currency and 5.2 percent EBITDA $561 million, up 8.4 percent at constant currency and 9.4 Diluted Earnings per Share $0.29 Diluted Earnings per Share $1.42, up 19
Read more →IQVIQVIA Reports Second-Quarter 2018 Results and Raises Full-Year 2018 Revenue and Profit Guidance Revenue $2,567 million, up 9.0 percent reported and 7.7 percent at constant currency Adjusted EBITDA $533 million, up 14.1 p
Reports Second-Quarter 2018 Results and Raises Full-Year 2018 Revenue $2,567 million, up 9.0 percent reported and 7.7 percent at constant EBITDA $533 million, up 14.1 percent reported and 14.3 percent at Diluted Earnings per Share $0.29 Diluted Earnings per Share $1.29, up 25
Read more →IQVIQVIA Reports First-Quarter 2018 Results and Raises Full-Year 2018 Revenue Guidance Revenue $2,563 million, up 8.6 percent reported and 5.2 percent at constant currency Adjusted EBITDA $547 million, up 8.5 percent report
Reports First-Quarter 2018 Results and Raises Full-Year 2018 Revenue $2,563 million, up 8.6 percent reported and 5.2 percent at constant EBITDA $547 million, up 8.5 percent reported and 7.4 percent at Diluted Earnings per Share $0.32 Diluted Earnings per Share $1.34, up 19.6
Read more →IQVIQVIA Reports Fourth-Quarter and Full-Year 2017 Results, Issues First-Quarter and Full-Year 2018 Guidance Revenue of $2,161 million for the fourth quarter and $8,060 million for the full year; $8,068 million of full-year
Reports Fourth-Quarter and Full-Year 2017 Results, Issues First-Quarter and Full-Year 2018 Guidance of $2,161 million for the fourth quarter and $8,060 million for the full year; $8,068 million of full-year revenue before merger-related deferred revenue adjustment EBITDA of
Read more →IQVAndrew Markwick, IQVIA Investor Relations (andrew.markwick@iqvia.com) +1.973.257.7144 Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com) +1.484.567.6732 QuintilesIMS is now IQVIA DANBURY, Conn.
Contacts: Andrew Markwick, IQVIA Investor Relations (andrew.markwick@iqvia.com) +1.973.257.7144 Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com) +1.484.567.6732 QuintilesIMS is now IQVIA DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C. (BUSINESS WIRE) Nove
Read more →IQVQuintilesIMS Reports Third-Quarter 2017 Results Revenue $2,019 million Adjusted EBITDA $512 million GAAP Diluted Earnings per Share $0.38; Adjusted Diluted Earnings per Share $1.19 $3.3 billion of share repurchase comple
Reports Third-Quarter 2017 Results Diluted Earnings per Share $0.38; Adjusted Diluted Earnings per Share billion of share repurchase completed post-merger, $557 million completed during the third quarter DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--October
Read more →IQVAndrew Markwick, QuintilesIMS Investor Relations ( andrew.markwick@quintilesims.com ) +1.973.257.7144 Tor Constantino, QuintilesIMS Media Relations ( tor.constantino@quintilesims.com ) +1.484.567.6732 Quintiles
Contacts: Andrew Markwick, QuintilesIMS Investor Relations ( andrew.markwick@quintilesims.com ) +1.973.257.7144 Tor Constantino, QuintilesIMS Media Relations ( tor.constantino@quintilesims.com ) +1.484.567.6732 QuintilesIMS Announces Offering of Senior Notes, Redemption of Ex
Read more →IQVAndrew Markwick, QuintilesIMS Investor Relations (andrew.markwick@quintilesims.com) +1.973.257.7144 Tor Constantino, QuintilesIMS Media Relations (tor.constantino@quintilesims.com) +1.484.567.6732
QuintilesIMS Announces Pricing on Offering of Senior Notes DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C. September 11, 2017 Quintiles IMS Holdings, Inc. ( QuintilesIMS ) (NYSE: Q) today announced the pricing of the offering of 420 million in gross proceeds of senior notes to be
Read more →IQVQuintilesIMS Reports Second-Quarter 2017 Results GAAP Revenue $1,969 million; $1,971 million before merger-related deferred Revenue adjustment Adjusted EBITDA $486 million GAAP Diluted Earnings per Share $0.34; Adjusted
QuintilesIMS Reports Second-Quarter 2017 Results GAAP Revenue $1,969 million; $1,971 million before merger-related deferred Revenue adjustment Adjusted EBITDA $486 million GAAP Diluted Earnings per Share $0.34; Adjusted Diluted Earnings per Share $1.09 $2.7 billion of share r
Read more →IQVQuintilesIMS Contacts: Tor Constantino, QuintilesIMS Media Relations ( tor.constantino@quintilesims.com ) +1.484.567.6732 Andrew Markwick, QuintilesIMS Investor Relations ( andrew.markwick@quintilesims.com ) +1.973.257.7
QuintilesIMS Contacts: Tor Constantino, QuintilesIMS Media Relations (tor.constantino@quintilesims.com) Markwick, QuintilesIMS Investor Relations (andrew.markwick@quintilesims.com) Colleen Goggins Joins QuintilesIMS Board of Directors DANBURY, Conn., & RESEARCH TRIANGLE PARK,
Read more →IQVIMS HEALTH HOLDINGS, INC. TABLE OF CONTENTS Page Condensed Consolidated Statements of Financial Position as of
IMS HEALTH HOLDINGS, INC. Page Condensed Consolidated Statements of Financial Position as of September 30, 2016 and December 31, 2015 2 Condensed Consolidated Statements of Comprehensive Income for the Three and Nine Months Ended September 30, 2016 and 2015 3 Condensed
Read more →IQVQuintilesIMS Reports First-Quarter 2017 Results and Raises Full-Year 2017 Adjusted Diluted EPS Guidance $1,911 million GAAP revenue; $1,917 million before merger-related deferred revenue adjustment $467 million Adjusted
Reports First-Quarter 2017 Results and Raises Full-Year 2017 Adjusted Diluted EPS Guidance million GAAP revenue; $1,917 million before merger-related deferred million Adjusted EBITDA Diluted Earnings per Share $0.31; Adjusted Diluted Earnings per Share billion in share repur
Read more →IQVAndrew Markwick, QuintilesIMS Investor Relations ( andrew.markwick@quintilesims.com ) +1.973.257.7144 Tor Constantino, QuintilesIMS Media Relations ( tor.constantino@quintilesims.com ) +1.484.567.6
Contacts: Andrew Markwick, QuintilesIMS Investor Relations ( andrew.markwick@quintilesims.com ) +1.973.257.7144 Tor Constantino, QuintilesIMS Media Relations ( tor.constantino@quintilesims.com ) +1.484.567.6732 Phil Bridges, QuintilesIMS Media Relations ( phil.bridges@quinti
Read more →IQVQuintilesIMS Reports Fourth-Quarter and Full-Year 2016 Results, Issues First-Quarter and Full-Year 2017 Guidance Revenue of $1,953 million, up 74.2 percent constant currency, 73.1 percent reported; on a combined company
Reports Fourth-Quarter and Full-Year 2016 Results, Issues First-Quarter and Full-Year 2017 Guidance of $1,953 million, up 74.2 percent constant currency, 73.1 percent reported; on a combined company basis up 4.2 percent constant currency, 3.5 percent at actual FX rates when a
Read more →IQVQuintilesIMS Announces Executive Leadership Changes Richard Staub III named president, Research & Development Solutions; Paul Spreen named executive vice president and chief customer officer; Thomas H. Pike to retire DAN
QuintilesIMS Announces Executive Leadership Changes Richard Staub III named president, Research & Development Solutions; Paul Spreen named executive vice president and chief customer officer; Thomas H. Pike to retire DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C., November 30,
Read more →IQVQuintilesIMS Reports Third-Quarter 2016 Results, Combined Company Guidance and Additional Merger Details Quintiles Third-Quarter 2016 Results Service revenue up 3.9 percent reported, 3.6 percent constant currency; Produc
Reports Third-Quarter 2016 Results, Combined Company Guidance and Additional Merger Details Third-Quarter 2016 Results revenue up 3.9 percent reported, 3.6 percent constant currency; Product Development revenue up 7.9 percent, 8.6 percent constant GAAP Earnings Per Share: $0
Read more →IQVNews For Immediate Release Contacts: Tor Constantino QuintilesIMS Media Relations tor.constantino@quintilesims.com +1.484.567.6732 (office / mobile) Phil Bridges QuintilesIMS Media Relations phil.bridges@quintilesims.com
News For Immediate Release Contacts: Tor Constantino QuintilesIMS Media Relations tor.constantino@quintilesims.com +1.484.567.6732 (office / mobile) Phil Bridges QuintilesIMS Media Relations phil.bridges@quintilesims.com +1.919.998.1653 (office) +1.919.457.6347 (mobile) Tom
Read more →IQVIMS Health Announces Pricing on Upsized Offering of Senior Notes In Connection with Quintiles IMS Merger DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)
Health Announces Pricing on Upsized Offering of Senior Notes In Connection with Quintiles IMS Merger DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--September 14, 2016--IMS Health Holdings, Inc. (NYSE:IMS) today announced the pricing of its offering of $1.75 b
Read more →IQVIMS Health Announces Offering of Senior Notes In Connection with Quintiles IMS Merger DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)
Health Announces Offering of Senior Notes In Connection with Quintiles DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--September 12, 2016--IMS Health Holdings, Inc. (NYSE:IMS) today announced that its wholly owned subsidiary, IMS Health Incorporated, intends t
Read more →IQVIMS Health and Quintiles Announce Key Officers for Merged Company DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)
Health and Quintiles Announce Key Officers for Merged Company DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--August 29, 2016--IMS Health Holdings, Inc. (NYSE:IMS) and Quintiles Transnational Holdings Inc. (NYSE:Q) today announced key senior management roles i
Read more →IQVQuintiles 2nd Quarter 2016 Results 8.6% service revenue growth, 7.9% at constant currency, compared to the second quarter of 2015 $0.93 diluted adjusted EPS representing 19.2% growth compared to the second quarter of 201
2nd Quarter 2016 Results service revenue growth, 7.9% at constant currency, compared to the second quarter of 2015 diluted adjusted EPS representing 19.2% growth compared to the second quarter of 2015, with $0.71 diluted GAAP EPS representing 6.0% growth billion of net new b
Read more →IQVQuintiles 1st Quarter 2016 Results Agreement to merge with IMS Health in all-stock transaction to create Quintiles IMS, an industry-leading information and technology-enabled healthcare services provider 8.4% constant cu
Quintiles 1st Quarter 2016 Results Park, NC, May 3, 2016 Quintiles Transnational Holdings Inc. ( Quintiles or the Company ) (NYSE: Q) today reported its financial results for the quarter ended March 31, 2016. For the three months ended March 31, 2016, the Company s service reve
Read more →IQVNews For Immediate Release Contacts: Tor Constantino IMS Health Media Relations +1.484.567.6732 tconstantino@us.imshealth.com Tom Kinsley IMS Health Investor Relations +1.203.448.4691 tkinsley@imshealth.com Phil Bridges
News For Immediate Release Contacts: Tor Constantino IMS Health Media Relations +1.484.567.6732 tconstantino@us.imshealth.com Tom Kinsley IMS Health Investor Relations +1.203.448.4691 tkinsley@imshealth.com Phil Bridges Quintiles Media Relations +1.919.998.1653 phil.bridges@qu
Read more →IQVQuintiles 4th Quarter and Full Year 2015 Results and 2016 Guidance 9.4% constant currency service revenue growth compared to the fourth quarter of 2014 $0.90 diluted adjusted EPS representing 26.8% growth compared to the
4th Quarter and Full Year 2015 Results and 2016 Guidance constant currency service revenue growth compared to the fourth diluted adjusted EPS representing 26.8% growth compared to the fourth quarter of 2014, fourth quarter GAAP reported diluted EPS of $0.85 business of $1.49
Read more →IQVPhil Bridges, Media Relations ( phil.bridges@quintiles.com ) + 1.919.998.1653 (office) +1.919.457.6347 (mobile) Todd Kasper, Investor Relations ( InvestorRelations@quintiles.com ) +1.919.998.2590 Founder Dennis
Contact: Phil Bridges, Media Relations ( phil.bridges@quintiles.com ) + 1.919.998.1653 (office) +1.919.457.6347 (mobile) Todd Kasper, Investor Relations ( InvestorRelations@quintiles.com ) +1.919.998.2590 Founder Dennis Gillings to Retire as Quintiles Executive Chairman
Read more →IQVQuintiles 3rd Quarter 2015 Results 8.3% constant currency service revenue growth compared to the third quarter of 2014 44.6% increase in diluted adjusted EPS to $0.94 per share compared to the third quarter of 2014, thir
3rd Quarter 2015 Results constant currency service revenue growth compared to the third quarter increase in diluted adjusted EPS to $0.94 per share compared to the third quarter of 2014, third quarter GAAP reported diluted EPS of $0.89 business of $1.16 billion, increasing ba
Read more →IQVPhil Bridges, Media Relations ( phil.bridges@quintiles.com ) + 1.919.998.1653 (office) +1.919.457.6347 (mobile) Todd Kasper, Investor Relations ( InvestorRelations@quintiles.com ) +1.919.998.2590 Quintiles Names
Contact: Phil Bridges, Media Relations ( phil.bridges@quintiles.com ) + 1.919.998.1653 (office) +1.919.457.6347 (mobile) Todd Kasper, Investor Relations ( InvestorRelations@quintiles.com ) +1.919.998.2590 Quintiles Names Kevin Gordon as COO, Appoints Mike McDonnell as CFO
Read more →IQVAnnie Hai-yuan Lo Elected to Quintiles Transnational Holdings Inc. Board of Directors RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)
Hai-yuan Lo Elected to Quintiles Transnational Holdings Inc. Board of RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--September 28, 2015--Quintiles Transnational Holdings Inc. ("Quintiles" or the "Company") (NYSE: Q) announced today that Annie Hai-yuan Lo, has been appointed t
Read more →IQVQuintiles Announces Closing of Secondary Public Offering Research Triangle Park, NC
Quintiles Announces Closing of Secondary Public Offering Research Triangle Park, NC, August 5, 2015 Quintiles Transnational Holdings Inc. ( Quintiles ) (NYSE: Q) announced today the closing of an underwritten, secondary public offering of 7,000,000 shares of its common stock by
Read more →IQVQuintiles 2nd Quarter 2015 Results 9.8% constant currency service revenue growth compared to the second quarter of 2014 20.0% increase in diluted adjusted EPS to $0.78 per share compared to the second quarter of 2014, se
2nd Quarter 2015 Results constant currency service revenue growth compared to the second increase in diluted adjusted EPS to $0.78 per share compared to the second quarter of 2014, second quarter GAAP reported diluted EPS of net new business growth compared to the second quar
Read more →IQVQuintiles Announces Closing of Secondary Public Offering And Repurchase of Common Stock Research Triangle Park, NC
Quintiles Announces Closing of Secondary Public Offering And Repurchase of Common Stock Research Triangle Park, NC, May 19, 2015 Quintiles Transnational Holdings Inc. ( Quintiles ) (NYSE: Q) announced today the closing of an underwritten, secondary public offering of 11,855,05
Read more →IQVQuintiles Announces Completion of Refinancing
Quintiles Announces Completion of Refinancing RESEARCH TRIANGLE PARK, N.C., May 12, 2015 Quintiles Transnational Holdings Inc. (NYSE: Q) (the Company or Quintiles ) today announced the completion of its previously announced refinancing. In the refinancing, the Company s wholly-
Read more →IQVQuintiles Announces Pricing of $800 Million Senior Notes Offering RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)
Announces Pricing of $800 Million Senior Notes Offering RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--May 6, 2015--Quintiles Transnational Holdings Inc. (NYSE: Q) (the "Company" or "Quintiles") announced today that Quintiles Transnational Corp. ("Quintiles Transnational"), i
Read more →IQVQuintiles Announces Proposed Offering of $800 Million of Senior Notes RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)
Announces Proposed Offering of $800 Million of Senior Notes RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--May 1, 2015--Quintiles Transnational Holdings Inc. (NYSE: Q) (the "Company" or "Quintiles") announced today a proposed offering by its wholly owned subsidiary, Quintiles
Read more →IQVQuintiles Announces Proposed Refinancing of Existing Indebtedness RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)
Announces Proposed Refinancing of Existing Indebtedness RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--April 29, 2015--Quintiles Transnational Holdings Inc. (the "Company" or "Quintiles") (NYSE: Q) announced today that it is proposing, subject to market and other conditions,
Read more →IQVQuintiles 1st Quarter 2015 Results $1.35 billion of net new business representing a 1.31 book-to-bill ratio 8.4% constant currency service revenue growth compared to the first quarter of 2014 $0.72 diluted adjusted earni
1st Quarter 2015 Results billion of net new business representing a 1.31 book-to-bill ratio constant currency service revenue growth compared to the first quarter diluted adjusted earnings per share representing 5.9% growth compared to the first quarter of 2014 and first quar
Read more →IQVQuintiles 4th Quarter 2014 Results and 2015 Guidance 22.2% growth in net new business compared to the fourth quarter of 2013 representing a book-to-bill ratio of 1.49 9.3% constant currency service revenue growth compare
4th Quarter 2014 Results and 2015 Guidance growth in net new business compared to the fourth quarter of 2013 representing a book-to-bill ratio of 1.49 constant currency service revenue growth compared to the fourth quarter diluted adjusted EPS increased 29.1% to $0.71 per sha
Read more →IQVPhil Bridges, Media Relations ( phil.bridges@quintiles.com ) + 1.919.998.1653 (office) +1.919.457.6347 (mobile) Karl Deonanan, Investor Relations ( InvestorRelations@quintiles.com ) +1.919.998.2789 Dr. John Leon
Contact: Phil Bridges, Media Relations ( phil.bridges@quintiles.com ) + 1.919.998.1653 (office) +1.919.457.6347 (mobile) Karl Deonanan, Investor Relations ( InvestorRelations@quintiles.com ) +1.919.998.2789 Dr. John Leonard Elected to Quintiles Transnational Holdings Inc
Read more →IQVQuintiles Reports 3rd Quarter 2014 Results 13.8% consolidated service revenue growth - Integrated Healthcare Services segment grew service revenues by 32.6% compared to the third quarter of 2013 Consolidated book-to-bill
Reports 3rd Quarter 2014 Results consolidated service revenue growth - Integrated Healthcare Services segment grew service revenues by 32.6% compared to the third quarter book-to-bill ratio of 1.42 results from 12.8% growth in net new business compared to the third quarter of
Read more →IQVQuintiles Reports 2nd Quarter 2014 Results 9.7% consolidated service revenue growth - Integrated Healthcare Services segment grew service revenues by 15.6% compared to the second quarter 2013 21.2% net new business growt
Reports 2nd Quarter 2014 Results consolidated service revenue growth - Integrated Healthcare Services segment grew service revenues by 15.6% compared to the second quarter net new business growth compared to the second quarter 2013 representing a book-to-bill ratio of 1.19 q
Read more →IQVQuintiles Reports First Quarter 2014 Results Over $1.0 billion of service revenues representing 8.4% growth; Integrated Healthcare Services segment grew service revenues by 6.0% in the quarter Net new business wins of $1
Reports First Quarter 2014 Results $1.0 billion of service revenues representing 8.4% growth; Integrated Healthcare Services segment grew service revenues by 6.0% in the business wins of $1.27 billion representing a book-to-bill ratio of quarter diluted adjusted EPS increased
Read more →IQVQuintiles Reports Fourth Quarter 2013 Results $1.0 billion of service revenues in the fourth quarter; First billion dollar service revenue quarter in Quintiles' history Net new business wins of $1.3 billion representing
Reports Fourth Quarter 2013 Results billion of service revenues in the fourth quarter; First billion dollar service revenue quarter in Quintiles' history business wins of $1.3 billion representing a book-to-bill ratio of 1.29 quarter diluted adjusted EPS increased 41% to $0.5
Read more →IQVRichard Relyea Elected to the Quintiles Transnational Holdings Inc. Board of Directors RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)
Relyea Elected to the Quintiles Transnational Holdings Inc. Board of RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--December 17, 2013--Quintiles announced today that Mr. Richard Relyea has been elected to its board of directors. Mr. Relyea was designated by equity investor 3i
Read more →IQVQuintiles Reports Third Quarter 2013 Results Net new business wins over $1.3 billion, up 29% compared to third quarter 2012; Backlog of $9.6 billion at the end of third quarter 2013 Third quarter diluted adjusted EPS of
Reports Third Quarter 2013 Results business wins over $1.3 billion, up 29% compared to third quarter 2012; Backlog of $9.6 billion at the end of third quarter 2013 quarter diluted adjusted EPS of $0.54 and adjusted net income of $71.9 million, up 20.0% and 36.7%, respectively
Read more →IQVQuintiles President & COO John Ratliff to Leave Company at End of 2013 RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)
President & COO John Ratliff to Leave Company at End of 2013 RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--October 31, 2013--Quintiles today announced that John Ratliff has resigned his position as president and chief operating officer (COO) effective December 31, 2013. He h
Read more →IQVQuintiles Reports Second Quarter 2013 Results and Full Year 2013 Guidance Net new business wins of $1.0 billion, up 13% compared to second quarter 2012; Backlog of $9.0 billion at the end of second quarter 2013 Second qu
Reports Second Quarter 2013 Results and Full Year 2013 Guidance business wins of $1.0 billion, up 13% compared to second quarter 2012; Backlog of $9.0 billion at the end of second quarter 2013 quarter diluted adjusted EPS of $0.50 and adjusted net income of $62.9 million, up
Read more →Competitive Position
How IQV ranks across every disease it competes inCompetitive Position is a premium feature
See how IQV ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial